(Q37763904)

22 August 2017

1 reference

title

Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis (English)

1 reference

22 August 2017

1 reference

Marie Hudson

1

1 reference

22 August 2017

Samy Suissa

series ordinal

2

1 reference

22 August 2017

publication date

1 June 2010

1 reference

Arthritis Care and Research

22 August 2017

published in

1 reference

22 August 2017

volume

62

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

805-810

1 reference

Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages

22 August 2017

cites work

1 reference

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

21 January 2018

1 reference

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use.

21 January 2018

1 reference

Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review

21 January 2018

1 reference

Channeling bias in the interpretation of drug effects

21 January 2018

1 reference

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

21 January 2018

1 reference

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

21 January 2018

1 reference

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

21 January 2018

1 reference

Immortal time bias in pharmaco-epidemiology

21 January 2018

1 reference

Immortal time bias in observational studies of drug effects

21 January 2018

1 reference

Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis

21 January 2018

1 reference

Why most published research findings are false

21 January 2018

1 reference

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ACR.20124

1 reference

22 August 2017

1 reference